Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROOKLYN) (H-52123)

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH (familial hypercholesterolemia) and LDL-C ≥ 70 mg/dL Who are Not Adequately Controlled by Their Lipid-Modifying Therapies

BROOKLYN is a clinical research study evaluating the safety and effectiveness of an investigational drug designed to lower cholesterol, specifically low-density lipoprotein cholesterol (LDL-C). LDL-C is known to be a harmful or “bad” form of cholesterol.

Study overview:

• Attend 8 study clinic visits over about 13 months.
• Take 1 tablet of either the assigned study drug or a placebo (no active ingredients) by mouth once daily for about 1 year.
• Continue taking your medication to lower cholesterol during the study that has been prescribed by your general practitioner (if applicable).
• Follow a cholesterol-lowering diet.

Key study requirements:

• You are 18 years of age or older.
• You have a family history of high cholesterol.
• You are taking medication(s) to lower cholesterol (if applicable). Examples of medications include:
• Statins such as atorvastatin (Lipitor®) [40 or 80 mg] and rosuvastatin (Crestor®) [20 or 40 mg]
• Ezetimibe (Zetia®) or bempedoic acid (Nexletol®)
• PCSK9-targeted therapies (such as Repatha®, Praluent®, or Legvio®)